FDA
-
-
-
-
-
-
-
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
-
-
-
-
-
-
-
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
-
-
-
-
-
-
-
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
TScan Therapeutics (TCRX) Announces CEO Transition
-
-
-
-
-
-
-
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
-
-
-
-
-
-
-
TScan Therapeutics, Inc (TCRX) Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic Malignancies
-
-
-
-
-
-
-
TScan Therapeutics, Inc (TCRX) Announces FDA Clearance of TSC-100 IND
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

